Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.61 |
| ▸ | CA2 | P00918 | 2/20 | 0.61 |
| ▸ | CA7 | P43166 | 2/20 | 0.61 |
| ▸ | CA9 | Q16790 | 2/20 | 0.61 |
| ▸ | CA12 | O43570 | 1/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.61 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL915383 | 0.87 | MAPT (0.71) | CA1CA2CA7CA9CA12 | |
| SCHEMBL13241216 | 0.85 | KDM4E (0.46) | CA1CA2CA7CA9CA12 | |
| SCHEMBL19862402 | 0.83 | CA1 (0.61) | CA1CA2CA7CA9CA12 | |
| SCHEMBL13940041 | 0.83 | CA1 (0.42) | CA1CA2CA7CA9CA12 | |
| SCHEMBL9563117 | 0.83 | RXFP1 (0.61) | CA1CA2ALDH1A1MEN1KMT2A | |
| SCHEMBL13338782 | 0.80 | EGFR (0.47) | CA1CA2CA7CA9CA12 | |
| SCHEMBL10996654 | 0.80 | ALDH1A1 (0.41) | ALDH1A1MEN1KMT2ATDP1MAPK1 | |
| SCHEMBL2544548 | 0.80 | CA1 (0.65) | CA1CA2CA7CA9CA12 | |
| SCHEMBL275936 | 0.79 | CA1 (0.55) | CA1CA2CA7CA9CA12 | |
| SCHEMBL2176392 | 0.79 | CA1 (0.55) | CA1CA2CA7CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116063063-B | Erosion-resistant shaping refractory material and preparation method thereof | 大城县宏大高温材料有限公司 | 2023-09-05 | — | — | CN | claimed |
| CN-116063063-A | Erosion-resistant shaping refractory material and preparation method thereof | 大城县宏大高温材料有限公司 | 2023-05-05 | — | — | CN | claimed |
| US-11827638-B2 | Imidazopyrrolopyridine as inhibitors of the JAK family of kinases | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-28 | — | — | US | disclosed |
| CN-116063063-B | Erosion-resistant shaping refractory material and preparation method thereof | 大城县宏大高温材料有限公司 | 2023-09-05 | — | — | CN | disclosed |
| CN-116063063-B | Erosion-resistant shaping refractory material and preparation method thereof | 大城县宏大高温材料有限公司 | 2023-09-05 | — | — | CN | disclosed |
| CN-116444483-A | Preparation method of 1,3-dithiane substituted diene derivative | 兰州大学 | 2023-07-18 | — | — | CN | disclosed |
| CN-116063063-A | Erosion-resistant shaping refractory material and preparation method thereof | 大城县宏大高温材料有限公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-116063063-A | Erosion-resistant shaping refractory material and preparation method thereof | 大城县宏大高温材料有限公司 | 2023-05-05 | — | — | CN | disclosed |
| EP-3555096-B1 | IMIDAZOPYRROLOPYRIDINE AS INHIBITORS OF THE JAK FAMILY OF KINASES | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-23 | — | — | EP | disclosed |
| CN-114685505-A | Imidazopyrrolopyridines as JAK family kinase inhibitors | 詹森药业有限公司 | 2022-07-01 | — | — | CN | disclosed |
| CN-110312719-B | Imidazopyrrolopyridines as JAK family kinase inhibitors | 詹森药业有限公司 | 2022-04-15 | — | — | CN | disclosed |
| US-7074523-B2 | Lithium secondary battery | HITACHI, LTD. (JP) | 2006-07-11 | — | — | US | disclosed |
| WO-2005044825-A1 | SILICON COMPOUNDS AND THEIR USE | AMEDIS PHARMACEUTICALS LTD. (GB) | 2005-05-19 | — | — | WO | disclosed |
| US-6852717-B2 | Compounds useful as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-02-08 | — | — | US | disclosed |
| US-20040106039-A1 | nonaqueous electrolytic solution containing a compound that is oxidized at a voltage > a charge end voltage of the battery and a compound which inhibits reactions at voltages < the charge end voltage | ARAI JUICHI (JP) | 2004-06-03 | — | — | US | disclosed |
| EP-1392661-A1 | DIARYLUREA DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20030008868-A1 | Compounds useful as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-01-09 | — | — | US | disclosed |
| US-20030003370-A1 | Nonaqueous electrolytic solution containing a compound which is oxidized at a voltage higher than a charge end voltage of the lithium secondary battery and a compound which inhibits reactions at voltages lower than said charge end voltage. | HITACHI, LTD. (JP) | 2003-01-02 | — | — | US | disclosed |
| WO-2002092576-A1 | DIARYLUREA DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2002-11-21 | — | — | WO | disclosed |
| EP-1258939-A2 | Lithium secondary battery | Hitachi, Ltd. (JP) | 2002-11-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827638-B2 | Imidazopyrrolopyridine as inhibitors of the JAK family of kinases | JAK1, JAK2, JAK3 | CA1 4821/4885CA2 4070/4885CA7 4853/4885 |
| US-20030008868-A1 | Compounds useful as anti-inflammatory agents | TNF, MPO, PTGES | CA1 4107/4885CA2 4104/4885CA7 4144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.